摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-溴-1H-咪唑 | 16681-56-4

中文名称
2-溴-1H-咪唑
中文别名
——
英文名称
2-bromo-1H-imidazole
英文别名
2-bromoimidazole;2-Bromimidazol
2-溴-1H-咪唑化学式
CAS
16681-56-4
化学式
C3H3BrN2
mdl
——
分子量
146.974
InChiKey
AXHRGVJWDJDYPO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    197-202 °C
  • 沸点:
    273.1±23.0 °C(Predicted)
  • 密度:
    1.904±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    6
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    28.7
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 危险品标志:
    Xn
  • 危险类别码:
    R22,R41,R37/38
  • WGK Germany:
    3
  • 海关编码:
    2933290090
  • 安全说明:
    S26,S39
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    请保持冷静。

SDS

SDS:39ada07cf8ec1179b6ffe12c208f7fac
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Bromo-1H-imidazole
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-1H-imidazole
CAS number: 16681-56-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C3H3BrN2
Molecular weight: 147.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-溴-1H-咪唑 在 sodium sulfite 作用下, 以 为溶剂, 反应 1.0h, 以97%的产率得到咪唑
    参考文献:
    名称:
    在水介质中用亚硫酸钠对苯酚和杂芳族化合物进行还原脱卤和脱卤磺化
    摘要:
    质子互变异构被用作在水介质中使用亚硫酸钠作为唯一试剂的(杂)芳基溴化物和碘化物的还原性脱卤化或(杂)芳基氯和氟化物的脱卤化磺化的工具。该方案不需要金属或相转移催化剂,避免使用有机溶剂作为反应介质。此方法特别适用于容易互变异构的底物(例如2-或4-卤代氨基酚和4-卤代间苯二酚),在温和的反应条件下(≤60°C)会进行脱卤或磺化。由于亚硫酸钠是一种廉价,安全且对环境无害的试剂,因此该方法至少具有三个潜在应用:(i)使用亚硫酸钠作为还原剂对卤素作为保护基进行脱保护;(ii)在温和的反应条件下磺化芳族卤化物,避免使用危险和腐蚀性的试剂/溶剂;(iii)将有毒的卤代芳族化合物转化为危害较小的化合物。
    DOI:
    10.1039/c9gc00467j
  • 作为产物:
    描述:
    参考文献:
    名称:
    [EN] PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE
    [FR] PTÉRIDINONES EN TANT QU'INHIBITEURS DE POLO-LIKE KINASE
    摘要:
    本发明提供了具有如下结构式(I)的化合物或其盐或溶剂化物,其中环A、X、R1、R2、R3、R4、R5和R6的定义如本文所述。本发明还提供了包括本发明化合物的药物组合物以及制造和使用本发明化合物和组合物的方法,例如,在治疗和预防各种疾病,如帕金森病。
    公开号:
    WO2011079114A1
点击查看最新优质反应信息

文献信息

  • [EN] 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS 2,3-DISUBSTITUÉS DE 1-ACYL-4-AMINO-1,2,3,4-TÉTRAHYDROQUINOLÉINE ET LEUR UTILISATION COMME INHIBITEURS DE BROMODOMAINES
    申请人:GLAXOSMITHKLINE IP NO 2 LTD
    公开号:WO2014140076A1
    公开(公告)日:2014-09-18
    The present invention relates to novel compounds of formula (I), wherein R1 is C1-4alkyl; R2 is C1-4alkyl, C3-7cycloalkyl, -CH2CF3, -CH2OCH3 or heterocyclyl; R3 is C1-4alkyl, -CH2F, -CH2OH or -CH2O(O)CH3; R4 when present is as defined in claim 1; R5 when present is H, halo, hydroxy or C1-6alkoxy; A is -NH-, -O-, -S-, -SO-, -SO2-, -N(C1-4alkyl)- or -NC(O)(CH3)-; V is phenyl, heteroaromatic or pyridone any of which may be optionally substituted by 1, 2 or 3 substituents; W is CH or N; X is C or N; Y is C or N; and Z is CH or N; subject to the proviso that no more than 2 of W, X, Y and Z are N, pharmaceutical compositions containing such compounds and to their use as bromodomain inhibitors.
    本发明涉及式(I)的新化合物,其中R1为C1-4烷基;R2为C1-4烷基、C3-7环烷基、-CH2CF3、-CH2OCH3或杂环烷基;R3为C1-4烷基、-CH2F、-CH2OH或-CH2O(O)CH3;R4存在时如权利要求1所定义;R5存在时为H、卤素、羟基或C1-6烷氧基;A为-NH-、-O-、-S-、-SO-、-SO2-、-N(C1-4烷基)-或-NC(O)(CH3)-;V为苯基、杂芳基或吡啶酮,其中任何一个可以选择性地被1、2或3个取代基取代;W为CH或N;X为C或N;Y为C或N;Z为CH或N;但W、X、Y和Z中不超过2个为N,含有这种化合物的药物组合物以及它们作为溴结构域抑制剂的用途。
  • [EN] 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS<br/>[FR] ANALOGUES DE PYRIDAZINE 1,4-DISUBSTITUÉE ET PROCÉDÉS DE TRAITEMENT DE TROUBLES LIÉS À UNE DÉFICIENCE EN SMN
    申请人:NOVARTIS AG
    公开号:WO2014028459A1
    公开(公告)日:2014-02-20
    The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    本发明提供了一种公式(I)的化合物或其药用可接受的盐;一种制造本发明化合物的方法及其治疗用途。本发明进一步提供了一种药物活性剂的组合物和一种药物组合物。
  • Synthesis and Structure–Activity Relationships of Tambjamines and B-Ring Functionalized Prodiginines as Potent Antimalarials
    作者:Papireddy Kancharla、Jane Xu Kelly、Kevin A. Reynolds
    DOI:10.1021/acs.jmedchem.5b00560
    日期:2015.9.24
    Synthesis and antimalarial activity of 94 novel bipyrrole tambjamines (TAs) and a library of B-ring functionalized tripyrrole prodiginines (PGs) against a panel of Plasmodium falciparum strains are described. The activity and structure–activity relationships demonstrate that the ring-C of PGs can be replaced by an alkylamine, providing for TAs with retained/enhanced potency. Furthermore, ring-B of
    描述了94种新型联吡咯他布明胺(TAs)的合成和抗疟活性以及针对一系列恶性疟原虫菌株的B环功能化三联吡咯酮(PGs)库。活性和结构-活性之间的关系表明,PGs的C环可以被烷基胺取代,从而为TAs提供保留/增强的效力。此外,PG / TA的B环可以在4位(取代OMe)或3位和4位上被短烷基取代而不影响效能。已评估了八个代表性TA和两个PG对耐多药疟原虫的抗疟活性口服给药的小鼠剂量范围为5-100 mg / kg×4天。KAR425 TA的功效比以前任何PG所观察到的都要大,在25天和50 mg / kg×4天的剂量下,直到28天之前,对感染疟疾的小鼠提供100%的保护,并且在该模型中也可以单次口服治疗(80毫克/公斤)。这项研究提出了tambjamines中抗疟活性的第一个解释。
  • [EN] COMPOUNDS AND THERAPEUTIC USES THEREOF<br/>[FR] COMPOSÉS ET SES UTILISATIONS THÉRAPEUTIQUES
    申请人:MYREXIS INC
    公开号:WO2012177782A1
    公开(公告)日:2012-12-27
    The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and complications associated with these diseases and disorders.
    这项发明涉及化合物、药物组合物和方法,用于治疗癌症、全身性或慢性炎症、类风湿性关节炎、糖尿病、肥胖症、T细胞介导的自身免疫疾病、缺血以及与这些疾病和疾病相关并发症。
  • [EN] IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS<br/>[FR] DÉRIVÉS D'IMIDAZOLE ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES AUTO-IMMUNES OU INFLAMMATOIRES OU DE CANCERS
    申请人:GLAXOSMITHKLINE IP NO 2 LTD
    公开号:WO2018041964A1
    公开(公告)日:2018-03-08
    Compounds of formula (I) and salts thereof: wherein R1, R2, R3, a, X1, X2, X3, X4, and X5 are as defined hereinbefore. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain containing proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.
    化合物的化学式(I)及其盐:其中R1、R2、R3、a、X1、X2、X3、X4和X5的定义如前所述。已发现化合物的化学式(I)及其盐能够抑制BET家族溴结构域蛋白与例如乙酰化赖氨酸残基的结合,因此可能在治疗中发挥作用,例如在治疗自身免疫和炎症性疾病(如类风湿性关节炎)和癌症方面。
查看更多

同类化合物

试剂2,5-Dibromo-3,4-dihexylthiophene 苯-1,2,4-三羧酸-丙烷-1,2,3-三醇(1:1) 碘吡咯 癸氯-二茂铁 溴代二茂铁 溴-(3-溴-2-噻嗯基)镁 派瑞林D 派瑞林 F 二聚体 氯代二茂铁 曲洛酯 异噻唑,3-氯-5-甲基- 地茂酮 四碘噻吩 四溴噻吩 四溴吡咯 四溴-N-甲基吡咯 四氯噻吩 四氟噻吩 噻菌腈 噻美尼定. 噻吩,3-溴-4-(1-辛炔基)- 噻吩,2,5-二氯-3,4-二(氯甲基)- 喷贝特 咪唑烷,2-(4-溴-5-甲基-2-呋喃基)-1,3-二甲基- 叔丁基2-溴-4,6-二氢-5H-吡咯并[3,4-D]噻唑-5-羧酸酯 叔-丁基2-溴-5,6-二氢咪唑并[1,2-A]吡嗪-7(8H)-甲酸基酯 八氟联苯烯 八氟二苯并硒吩 二苯基氯化碘盐 二联苯碘硫酸盐 二氯对二甲苯二聚体 二氯[2-甲基-3(2H)-异噻唑酮-O]的钙合物 二氯-1,2-二硫环戊烯酮 二-(3-溴-1,2,4-噻二唑-5-基)-二硫醚 二(2-噻吩基)碘鎓 [四丁基铵][Δ-三(四氯-1,2-苯二醇酸根)磷酸盐(V)] [3-(4-氯-3,5-二甲基-1H-吡唑-1-基)丙基]胺 [3-(4-氯-1H-吡唑-1-基)-2-甲基丙基]胺 [2-(4-溴-吡唑-1-基)-乙基]-二甲胺 [1-(4-溴-3-甲基-1,2-噻唑-5-基)乙亚基氨基]硫脲 [1-(4-溴-1,2-噻唑-3-基)乙亚基氨基]硫脲 [1,1'-联苯]-2,2'-二基碘鎓 [(4-碘-1,2-噻唑-5-基)亚甲基氨基]硫脲 [(4-氯-1,2-噻唑-5-基)亚甲基氨基]硫脲 N-苄基-2-氯吡咯 N-Boc-2-氨基-3-溴噻吩 N-(2-氯-4-甲基-3-噻吩)-4,5-二氢-1H-咪唑-2-胺盐酸盐 N-(2,5-二溴-1H-吡咯-1-基)-氨基甲酸叔丁酯 N,N-二甲基-5-碘-1H-吡唑-1-磺酰胺 N,N-二甲基-2-(3,4,5-三溴吡唑-1-基)丙酰胺